Skip to main content
SpringerLink
Log in

Personalized Management of Atopic Dermatitis: Beyond Emollients and Topical Steroids

  • Chapter
  • First Online:
Personalized Treatment Options in Dermatology

Abstract

Atopic dermatitis (AD) is a complex and multifactorial disease which we are just beginning to understand in terms of its heterogeneous genetic and pathophysiological nature. Personalised medicine offers us the unique opportunity to tailor the management of AD based on the presence or absence of key biomarkers. For example, filaggrin mutations might be potentially useful as markers to predict the course of AD in individual patients. Other biomarkers might help us to predict the risk of developing IgE-sensitization in some patients. Thus, the genotype and other biological information located on a key set of biomarkers (the so-called endophenotype) could help us to identify those patients who would benefit most from early intervention with the aim of stopping the “atopic march”. In addition, patient stratification might eventually enable us to identify those patients who are receptive to long-term management with treatments that may reverse the “atopic march”. Thus, we are at the beginning of a new era in our understanding of the complexity of AD; an era in which established prevention strategies and new therapies might be applied in a selective manner to target the right patients more effectively at the right time.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–94.

    CAS  PubMed  Google Scholar 

  2. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69(1):​3–16. Epub 2014/01/15.

    CAS  PubMed  Google Scholar 

  3. Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res. 2014;306(3):279–86. Epub 2013/08/29.

    CAS  PubMed  Google Scholar 

  4. Beattie PE, Lewis-Jones MS. An audit of the impact of a consultation with a paediatric dermatology team on quality of life in infants with atopic eczema and their families: further validation of the Infants’ Dermatitis Quality of Life Index and Dermatitis Family Impact score. Br J Dermatol. 2006;155(6):1249–55.

    CAS  PubMed  Google Scholar 

  5. Zuberbier T, Orlow SJ, Paller AS, Taieb A, Allen R, Hernanz-Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226–32.

    PubMed  Google Scholar 

  6. Healy E, Bentley A, Fidler C, Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol. 2011;164(2):387–95. Epub 2010/11/19.

    CAS  PubMed  Google Scholar 

  7. Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol. 2008;25(1):1–6.

    PubMed  Google Scholar 

  8. Jenner N, Campbell J, Marks R. Morbidity and cost of atopic eczema in Australia. Australas J Dermatol. 2004;45(1):16–22.

    PubMed  Google Scholar 

  9. Lamb SR, Rademaker M. Pharmacoeconomics of drug therapy for atopic dermatitis. Expert Opin Pharmacother. 2002;3(3):249–55.

    PubMed  Google Scholar 

  10. Herd RM. The financial impact on families of children with atopic dermatitis. Arch Dermatol. 2002;138(6):819–20.

    PubMed  Google Scholar 

  11. Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewicz M, Daniel CR, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol. 2002;46(3):361–70.

    PubMed  Google Scholar 

  12. Curtiss FR. Prevalence and costs of atopic dermatitis. J Manag Care Pharm. 2002;8(5):404.

    Google Scholar 

  13. Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol. 2001;144(3):514–22.

    CAS  PubMed  Google Scholar 

  14. Kemp AS. Atopic eczema: its social and financial costs. J Paediatr Child Health. 1999;35(3):229–31.

    CAS  PubMed  Google Scholar 

  15. Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997;76(2):159–62.

    PubMed Central  CAS  PubMed  Google Scholar 

  16. Herd RM, Tidman MJ, Prescott RJ, Hunter JA. The cost of atopic eczema. Br J Dermatol. 1996;135(1):20–3.

    CAS  PubMed  Google Scholar 

  17. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: who cares? Who pays? J Am Acad Dermatol. 1993;28(5 Pt 1):699–703.

    CAS  PubMed  Google Scholar 

  18. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med. 2005;352(22):2314–24.

    CAS  PubMed  Google Scholar 

  19. Bieber T, Bussmann C. Atopic dermatitis. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. Oxford: Elsevier; 2012.

    Google Scholar 

  20. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–51. Epub 2013/12/03.

    PubMed  Google Scholar 

  21. Rubel D, Thirumoorthy T, Soebaryo RW, Weng SC, Gabriel TM, Villafuerte LL, et al. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. J Dermatol. 2013;40(3):160–71. Epub 2013/01/08.

    CAS  PubMed  Google Scholar 

  22. Devillers AC, Oranje AP. Wet-wrap treatment in children with atopic dermatitis: a practical guideline. Pediatr Dermatol. 2012;29(1):24–7. Epub 2012/01/20.

    PubMed  Google Scholar 

  23. Katayama I, Kohno Y, Akiyama K, Ikezawa Z, Kondo N, Tamaki K, et al. Japanese guideline for atopic dermatitis. Allergol Int. 2011;60(2):205–20. Epub 2011/06/04.

    CAS  PubMed  Google Scholar 

  24. Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I, et al. Guidelines for management of atopic dermatitis. J Dermatol. 2009;36(10):563–77.

    PubMed  Google Scholar 

  25. Baumer JH. Guideline review: atopic eczema in children, NICE. Arch Dis Child Educ Pract Ed 2008;93(3):93–97.

    CAS  PubMed  Google Scholar 

  26. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines”. J Am Acad Dermatol. 2004;50(3):391–404.

    PubMed  Google Scholar 

  27. Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy. 2004;59 Suppl 78:86–92.

    PubMed  Google Scholar 

  28. Guillet MH, Guillet G. Management of atopic dermatitis: practical guidelines suggested by the conclusion of systematic assessment in 500 children. Allerg Immunol (Paris). 2000;32(8):305–8. La prise en charge allergologique de l’atopique eczemateux: conclusions pratiques de l’exploration systematique de 500 enfants.

    CAS  Google Scholar 

  29. McNally NJ, Williams HC, Phillips DR, Smallman-Raynor M, Lewis S, Venn A, et al. Atopic eczema and domestic water hardness. Lancet. 1998;352(9127):527–31.

    CAS  PubMed  Google Scholar 

  30. Thomas KS, Sach TH. A multicentre randomized controlled trial of ion-exchange water softeners for the treatment of eczema in children: protocol for the Softened Water Eczema Trial (SWET) (ISRCTN: 71423189). Br J Dermatol. 2008;159(3):561–6.

    Google Scholar 

  31. Thomas KS, Dean T, O’Leary C, Sach TH, Koller K, Frost A, et al. A randomised controlled trial of ion-exchange water softeners for the treatment of eczema in children. PLoS Med. 2011;8(2):e1000395. Epub 2011/03/02.

    PubMed Central  PubMed  Google Scholar 

  32. Chaumont A, Voisin C, Sardella A, Bernard A. Interactions between domestic water hardness, infant swimming and atopy in the development of childhood eczema. Environ Res. 2012;116:52–7. Epub 2012/05/18.

    CAS  PubMed  Google Scholar 

  33. Parazzini F, Cipriani S, Zinetti C, Chatenoud L, Frigerio L, Amuso G, et al. Perinatal factors and the risk of atopic dermatitis: a cohort study. Pediatr Allergy Immunol. 2014;25(1):43–50. Epub 2013/12/10.

    PubMed  Google Scholar 

  34. Kim JH, Jeong KS, Ha EH, Park H, Ha M, Hong YC, et al. Relationship between prenatal and postnatal exposures to folate and risks of allergic and respiratory diseases in early childhood. Pediatr Pulmonol. 2014. Epub 2014/03/13.

    Google Scholar 

  35. Illi S, Weber J, Zutavern A, Genuneit J, Schierl R, Strunz-Lehner C, et al. Perinatal influences on the development of asthma and atopy in childhood. Ann Allergy Asthma Immunol. 2014;112(2):132–9 e1. Epub 2014/01/29.

    PubMed  Google Scholar 

  36. Bunyavanich S, Rifas-Shiman SL, Platts-Mills TA, Workman L, Sordillo JE, Camargo Jr CA, et al. Peanut, milk, and wheat intake during pregnancy is associated with reduced allergy and asthma in children. J Allergy Clin Immunol. 2014;133(5):1373–82.

    Google Scholar 

  37. Chen CM, Sausenthaler S, Bischof W, Herbarth O, Borte M, Behrendt H, et al. Perinatal exposure to endotoxin and the development of eczema during the first 6 years of life. Clin Exp Dermatol. 2010;35(3):238–244.

    Google Scholar 

  38. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69(1):17–27. Epub 2013/10/15.

    CAS  PubMed  Google Scholar 

  39. Illi S, von Mutius E, Lau S, Nickel R, Gruber C, Niggemann B, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925–31.

    PubMed  Google Scholar 

  40. Lack G. Update on risk factors for food allergy. J Allergy Clin Immunol. 2012;129(5):1187–97. Epub 2012/04/03.

    PubMed  Google Scholar 

  41. Roduit C, Frei R, Depner M, Schaub B, Loss G, Genuneit J, et al. Increased food diversity in the first year of life is inversely associated with allergic diseases. J Allergy Clin Immunol. 2014;133(4):1056–64 e7. Epub 2014/02/11.

    PubMed  Google Scholar 

  42. Roduit C, Frei R, Loss G, Buchele G, Weber J, Depner M, et al. Development of atopic dermatitis according to age of onset and association with early-life exposures. J Allergy Clin Immunol. 2012;130(1):130–6 e135.

    Google Scholar 

  43. Brauweiler AM, Goleva E, Leung DY. Th2 cytokines increase staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol. 2014;134(8):2114–21.

    Google Scholar 

  44. Reginald K, Westritschnig K, Werfel T, Heratizadeh A, Novak N, Focke-Tejkl M, et al. Immunoglobulin E antibody reactivity to bacterial antigens in atopic dermatitis patients. Clin Exp Allergy. 2011;41(3):357–69. Epub 2010/12/16.

    PubMed Central  CAS  PubMed  Google Scholar 

  45. Leung AD, Schiltz AM, Hall CF, Liu AH. Severe atopic dermatitis is associated with a high burden of environmental Staphylococcus aureus. Clin Exp Allergy. 2008;38(5):789–93.

    CAS  PubMed  Google Scholar 

  46. Cardona ID, Cho SH, Leung DY. Role of bacterial superantigens in atopic dermatitis: implications for future therapeutic strategies. Am J Clin Dermatol. 2006;7(5):273–9.

    PubMed  Google Scholar 

  47. Travers JB, Kozman A, Yao Y, Ming W, Yao W, Turner MJ, et al. Treatment outcomes of secondarily impetiginized pediatric atopic dermatitis lesions and the role of oral antibiotics. Pediatr Dermatol. 2012;29(3):289–96. Epub 2011/12/14.

    PubMed Central  PubMed  Google Scholar 

  48. Ong PY, Leung DY. The infectious aspects of atopic dermatitis. Immunol Allergy Clin North Am. 2010;30(3):309–21. Epub 2010/07/31.

    PubMed Central  PubMed  Google Scholar 

  49. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125(1):4–13; quiz 4–5. Epub 2010/01/30.

    PubMed Central  PubMed  Google Scholar 

  50. Kong HH, Segre JA. Skin microbiome: looking back to move forward. J Invest Dermatol. 2012;132(3 Pt 2):933–9. Epub 2011/12/23.

    PubMed Central  CAS  PubMed  Google Scholar 

  51. Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC. Low diversity of the gut microbiota in infants with atopic eczema. J Allergy Clin Immunol. 2012;129(2):434–40, ​40 e1–2. Epub 2011/12/14.

    PubMed  Google Scholar 

  52. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science. 2009;326(5960):1694–7. Epub 2009/11/07.

    PubMed Central  CAS  PubMed  Google Scholar 

  53. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009;324(5931):1190–2. Epub 2009/05/30.

    PubMed Central  CAS  PubMed  Google Scholar 

  54. Zhou Y, Gao H, Mihindukulasuriya KA, La Rosa PS, Wylie KM, Vishnivetskaya T, et al. Biogeography of the ecosystems of the healthy human body. Genome Biol. 2013;14(1):R1. Epub 2013/01/16.

    PubMed Central  PubMed  Google Scholar 

  55. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–9. Epub 2012/02/09.

    PubMed Central  CAS  PubMed  Google Scholar 

  56. Castelino M, Eyre S, Upton M, Ho P, Barton A. The bacterial skin microbiome in psoriatic arthritis, an unexplored link in pathogenesis: challenges and opportunities offered by recent technological advances. Rheumatology. 2014;53(5):777–84.

    Google Scholar 

  57. Chen YE, Tsao H. The skin microbiome: current perspectives and future challenges. J Am Acad Dermatol. 2013;69(1):143–55. Epub 2013/03/16.

    PubMed Central  CAS  PubMed  Google Scholar 

  58. Zeeuwen PL, Kleerebezem M, Timmerman HM, Schalkwijk J. Microbiome and skin diseases. Curr Opin Allergy Clin Immunol. 2013;13(5):514–20. Epub 2013/08/27.

    CAS  PubMed  Google Scholar 

  59. Benjamin K, Waterston K, Russell M, Schofield O, Diffey B, Rees JL. The development of an objective method for measuring scratch in children with atopic dermatitis suitable for clinical use. J Am Acad Dermatol. 2004;50(1):33–40.

    PubMed  Google Scholar 

  60. Kinaciyan T, Natter S, Kraft D, Stingl G, Valenta R. IgE autoantibodies monitored in a patient with atopic dermatitis under cyclosporin A treatment reflect tissue damage. J Allergy Clin Immunol. 2002;109(4):717–9.

    PubMed  Google Scholar 

  61. Tang TS, Bieber T, Williams HC. Does “autoreactivity” play a role in atopic dermatitis? J Allergy Clin Immunol. 2012;129(5):1209–15 e2. Epub 2012/03/14.

    PubMed  Google Scholar 

  62. Altrichter S, Kriehuber E, Moser J, Valenta R, Kopp T, Stingl G. Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. J Invest Dermatol. 2008;128(9):2232–9.

    CAS  PubMed  Google Scholar 

  63. Valenta R, Seiberler S, Natter S, Mahler V, Mossabeb R, Ring J, et al. Autoallergy: a pathogenetic factor in atopic dermatitis? J Allergy Clin Immunol. 2000;105(3):432–7.

    CAS  PubMed  Google Scholar 

  64. Valenta R, Natter S, Seiberler S, Wichlas S, Maurer D, Hess M, et al. Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. J Invest Dermatol. 1998;111(6):1178–83.

    CAS  PubMed  Google Scholar 

  65. Valenta R, Maurer D, Steiner R, Seiberler S, Sperr WR, Valent P, et al. Immunoglobulin E response to human proteins in atopic patients. J Invest Dermatol. 1996;107(2):203–8.

    CAS  PubMed  Google Scholar 

  66. Mothes N, Niggemann B, Jenneck C, Hagemann T, Weidinger S, Bieber T, et al. The cradle of IgE autoreactivity in atopic eczema lies in early infancy. J Allergy Clin Immunol. 2005;116(3):706–9.

    CAS  PubMed  Google Scholar 

  67. Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet. 2006;38(3):337–42.

    CAS  PubMed  Google Scholar 

  68. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–6.

    CAS  PubMed  Google Scholar 

  69. Kezic S, O’Regan GM, Yau N, Sandilands A, Chen H, Campbell LE, et al. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy. 2011;66(7):934–40. Epub 2011/01/26.

    PubMed Central  CAS  PubMed  Google Scholar 

  70. Marenholz I, Nickel R, Ruschendorf F, Schulz F, Esparza-Gordillo J, Kerscher T, et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol. 2006;118(4):866–71.

    CAS  PubMed  Google Scholar 

  71. Schuttelaar ML, Kerkhof M, Jonkman MF, Koppelman GH, Brunekreef B, de Jongste JC, et al. Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposure. Allergy. 2009;64(12):1758–65.

    Google Scholar 

  72. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105(2):99–106; quiz 7–9, 17. Epub 2010/08/03.

    CAS  PubMed  Google Scholar 

  73. Heimall J, Spergel JM. Filaggrin mutations and atopy: consequences for future therapeutics. Expert Rev Clin Immunol. 2012;8(2):189–97. Epub 2012/02/01.

    CAS  PubMed  Google Scholar 

  74. Burgess JA, Lowe AJ, Matheson MC, Varigos G, Abramson MJ, Dharmage SC. Does eczema lead to asthma? J Asthma. 2009;46(5):429–36.

    PubMed  Google Scholar 

  75. Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):209–13.

    PubMed  Google Scholar 

  76. Spergel JM. Atopic march: link to upper airways. Curr Opin Allergy Clin Immunol. 2005;5(1):17–21.

    PubMed  Google Scholar 

  77. Walley AJ, Chavanas S, Moffatt MF, Esnouf RM, Ubhi B, Lawrence R, et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet. 2001;29(2):175–8.

    CAS  PubMed  Google Scholar 

  78. Sprecher E, Chavanas S, DiGiovanna JJ, Amin S, Nielsen K, Prendiville JS, et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J Invest Dermatol. 2001;117(2):179–87.

    CAS  PubMed  Google Scholar 

  79. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009;206(5):1135–47.

    PubMed Central  CAS  PubMed  Google Scholar 

  80. Di WL, Hennekam RC, Callard RE, Harper JI. A heterozygous null mutation combined with the G1258A polymorphism of SPINK5 causes impaired LEKTI function and abnormal expression of skin barrier proteins. Br J Dermatol. 2009;161(2):404–12.

    Google Scholar 

  81. Meyer-Hoffert U, Wu Z, Schroder JM. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor. PLoS One. 2009;4(2):e4372.

    PubMed Central  PubMed  Google Scholar 

  82. Briot A, Lacroix M, Robin A, Steinhoff M, Deraison C, Hovnanian A. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J Invest Dermatol. 2010;130(12):2736–42. Epub 2010/08/13.

    CAS  PubMed  Google Scholar 

  83. Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res. 2013;351(2):289–300. Epub 2013/01/25.

    CAS  PubMed  Google Scholar 

  84. Weidinger S, Willis-Owen SA, Kamatani Y, Baurecht H, Morar N, Liang L, et al. A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis. Hum Mol Genet. 2013;22(23):4841–56. Epub 2013/07/28.

    Google Scholar 

  85. Ellinghaus D, Baurecht H, Esparza-Gordillo J, Rodriguez E, Matanovic A, Marenholz I, et al. High-density genotyping study identifies four new susceptibility loci for atopic dermatitis. Nat Genet. 2013;45(7):808–12. Epub 2013/06/04.

    PubMed Central  CAS  PubMed  Google Scholar 

  86. Bonnelykke K, Matheson MC, Pers TH, Granell R, Strachan DP, Alves AC, et al. Meta-analysis of genome-wide association studies identifies ten loci influencing allergic sensitization. Nat Genet. 2013;45(8):902–6. Epub 2013/07/03.

    CAS  PubMed  Google Scholar 

  87. Sun LD, Xiao FL, Li Y, Zhou WM, Tang HY, Tang XF, et al. Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. Nat Genet. 2011;43(7):​690–4. Epub 2011/06/15.

    CAS  PubMed  Google Scholar 

  88. Paternoster L, Standl M, Chen CM, Ramasamy A, Bonnelykke K, Duijts L, et al. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat Genet. 2012;44(2):187–92. Epub 2011/12/27.

    Google Scholar 

  89. Beyer K, Nickel R, Freidhoff L, Bjorksten B, Huang SK, Barnes KC, et al. Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. J Invest Dermatol. 2000;115(5):906–8.

    CAS  PubMed  Google Scholar 

  90. Soderhall C, Bradley M, Kockum I, Wahlgren CF, Luthman H, Nordenskjold M. Linkage and association to candidate regions in Swedish atopic dermatitis families. Hum Genet. 2001;109(2):129–35.

    CAS  PubMed  Google Scholar 

  91. Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Fujita H, et al. Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci. 2002;30(2):161–6. Epub 2002/11/05.

    CAS  PubMed  Google Scholar 

  92. Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med. 1997;337(24):1720–5.

    CAS  PubMed  Google Scholar 

  93. Biagini Myers JM, Wang N, Lemasters GK, Bernstein DI, Epstein TG, Lindsey MA, et al. Genetic and environmental risk factors for childhood eczema development and allergic sensitization in the CCAAPS Cohort. J Invest Dermatol. 2010;130(2):430–437.

    Google Scholar 

  94. Turner MJ, Zhou B. A new itch to scratch for TSLP. Trends Immunol. 2014;35(2):49–50. Epub 2014/01/15.

    PubMed Central  CAS  PubMed  Google Scholar 

  95. Margolis DJ, Kim B, Apter AJ, Gupta J, Hoffstad O, Papadopoulos M, et al. Thymic stromal lymphopoietin variation, filaggrin loss of function, and the persistence of atopic dermatitis. JAMA Dermatol. 2014;150(3):254–9. Epub 2014/01/10.

    PubMed  Google Scholar 

  96. Leyva-Castillo JM, Hener P, Jiang H, Li M. TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice. J Invest Dermatol. 2013;133(1):154–63. Epub 2012/07/27.

    CAS  PubMed  Google Scholar 

  97. Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol. 2010;11(4):289–93. Epub 2010/03/20.

    PubMed Central  CAS  PubMed  Google Scholar 

  98. Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013;68(8):974–82. Epub 2013/07/31.

    CAS  PubMed  Google Scholar 

  99. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119(12):3573–85. Epub 2009/11/19.

    PubMed Central  CAS  PubMed  Google Scholar 

  100. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, et al. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009;123(6):1244–52 e2.

    PubMed Central  CAS  PubMed  Google Scholar 

  101. Niebuhr M, Scharonow H, Gathmann M, Mamerow D, Werfel T. Staphylococcal exotoxins are strong inducers of IL-22: a potential role in atopic dermatitis. J Allergy Clin Immunol. 2010;126(6):1176–83 e4. Epub 2010/09/25.

    CAS  PubMed  Google Scholar 

  102. Souwer Y, Szegedi K, Kapsenberg ML, de Jong EC. IL-17 and IL-22 in atopic allergic disease. Curr Opin Immunol. 2010;22(6):821–6. Epub 2010/11/23.

    CAS  PubMed  Google Scholar 

  103. Auriemma M, Vianale G, Amerio P, Reale M. Cytokines and T cells in atopic dermatitis. Eur Cytokine Netw. 2013;24(1):37–44. Epub 2013/04/24.

    CAS  PubMed  Google Scholar 

  104. Yao W, Zhang Y, Jabeen R, Nguyen ET, Wilkes DS, Tepper RS, et al. Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. Immunity. 2013;38(2):360–72. Epub 2013/02/05.

    PubMed Central  CAS  PubMed  Google Scholar 

  105. Ma L, Xue HB, Guan XH, Shu CM, Zhang JH, Yu J. Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. Clin Exp Immunol. 2014;175(1):25–31. Epub 2013/09/17.

    PubMed Central  CAS  PubMed  Google Scholar 

  106. Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC activated Th2 memory cells. J Exp Med. 2007;204(8):1837–47.

    PubMed Central  CAS  PubMed  Google Scholar 

  107. Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran M. IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction? J Invest Dermatol. 2010;130(2):430–437.

    Google Scholar 

  108. Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran M. IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction? J Invest Dermatol. 2011;131(1):150–7. Epub 2010/09/24.

    CAS  PubMed  Google Scholar 

  109. Deleuran M, Hvid M, Kemp K, Christensen GB, Deleuran B, Vestergaard C. IL-25 induces both inflammation and skin barrier dysfunction in atopic dermatitis. Chem Immunol Allergy. 2012;96:45–9. Epub 2012/03/22.

    CAS  PubMed  Google Scholar 

  110. Luo Y, Zhou B, Zhao M, Tang J, Lu Q. Promoter demethylation contributes to TSLP overexpression in skin lesions of patients with atopic dermatitis. Clin Exp Dermatol. 2014;39(1):48–53. Epub 2013/12/18.

    CAS  PubMed  Google Scholar 

  111. Wang IJ, Chen SL, Lu TP, Chuang EY, Chen PC. Prenatal smoke exposure, DNA methylation, and childhood atopic dermatitis. Clin Exp Allergy. 2013;43(5):535–43. Epub 2013/04/23.

    CAS  PubMed  Google Scholar 

  112. van Panhuys N, Le Gros G, McConnell MJ. Epigenetic regulation of Th2 cytokine expression in atopic diseases. Tissue Antigens. 2008;72(2):91–7. Epub 2008/06/17.

    PubMed  Google Scholar 

  113. Han J, Park SG, Bae JB, Choi J, Lyu JM, Park SH, et al. The characteristics of genome-wide DNA methylation in naive CD4+ T cells of patients with psoriasis or atopic dermatitis. Biochem Biophys Res Commun. 2012;422(1):157–63. Epub 2012/05/09.

    CAS  PubMed  Google Scholar 

  114. Liang Y, Wang P, Zhao M, Liang G, Yin H, Zhang G, et al. Demethylation of the FCER1G promoter leads to FcepsilonRI overexpression on monocytes of patients with atopic dermatitis. Allergy. 2012;67(3):424–30. Epub 2011/12/14.

    CAS  PubMed  Google Scholar 

  115. Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013;68(4):498–506. Epub 2013/03/05.

    CAS  PubMed  Google Scholar 

  116. Roguedas-Contios AM, Misery L. What is intrinsic atopic dermatitis? Clin Rev Allergy Immunol. 2011;41(3):233–6. Epub 2011/05/25.

    PubMed  Google Scholar 

  117. Pugliarello S, Cozzi A, Gisondi P, Girolomoni G. Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges. 2011;9(1):12–20. Epub 2010/11/09.

    PubMed  Google Scholar 

  118. Katsarou A, Armenaka M. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol. 2011;25(1):12–8. Epub 2010/06/24.

    CAS  PubMed  Google Scholar 

  119. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci. 2010;58(1):1–7. Epub 2010/03/09.

    CAS  PubMed  Google Scholar 

  120. Ott H, Stanzel S, Ocklenburg C, Merk HF, Baron JM, Lehmann S. Total serum IgE as a parameter to differentiate between intrinsic and extrinsic atopic dermatitis in children. Acta Derm Venereol. 2009;89(3):257–61.

    PubMed  Google Scholar 

  121. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol. 2003;112(2):252–62.

    PubMed  Google Scholar 

  122. Ozkaya E. Adult-onset atopic dermatitis. J Am Acad Dermatol. 2005;52(4):579–82.

    PubMed  Google Scholar 

  123. Asai T, Horiuchi Y. Senile erythroderma with serum hyper IgE. Int J Dermatol. 1989;28(4):255–8.

    CAS  PubMed  Google Scholar 

  124. Tanei R, Katsuoka K. Clinical analyses of atopic dermatitis in the aged. J Dermatol. 2008;35(9):562–9.

    PubMed  Google Scholar 

  125. Tanei R. Atopic dermatitis in the elderly. Inflamm Allergy Drug Targets. 2009;8(5):398–404.

    CAS  PubMed  Google Scholar 

  126. Lancrajan C, Bumbacea R, Giurcaneanu C. Erythrodermic atopic dermatitis with late onset – case presentation. J Med Life. 2010;3(1):80–3. Epub 2010/03/23.

    PubMed Central  PubMed  Google Scholar 

  127. Roth HL, Kierland RR. The natural history of atopic dermatitis. A 20-year follow-up study. Arch Dermatol. 1964;89:209–14.

    CAS  PubMed  Google Scholar 

  128. Williams HC, Strachan DP. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol. 1998;139(5):834–9.

    CAS  PubMed  Google Scholar 

  129. Taieb A. The natural history of atopic dermatitis. J Am Acad Dermatol. 2001;45(1 Suppl):S4–5; discussion S-6.

    CAS  PubMed  Google Scholar 

  130. Kadyk DL, McCarter K, Achen F, Belsito DV. Quality of life in patients with allergic contact dermatitis. J Am Acad Dermatol. 2003;49(6):1037–48.

    PubMed  Google Scholar 

  131. Stone KD. Atopic diseases of childhood. Curr Opin Pediatr. 2003;15(5):495–511.

    PubMed  Google Scholar 

  132. Perkin MR, Strachan DP, Williams HC, Kennedy CT, Golding J. Natural history of atopic dermatitis and its relationship to serum total immunoglobulin E in a population-based birth cohort study. Pediatr Allergy Immunol. 2004;15(3):221–9.

    PubMed  Google Scholar 

  133. Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol. 2014;150(6):593–600. Epub 2014/04/04.

    Google Scholar 

  134. Kim WJ, Ko HC, Kim MB, Kim DW, Kim JM, Kim BS. Features of Staphylococcus aureus colonization in patients with nummular eczema. Br J Dermatol. 2013;168(3):658–60. Epub 2012/05/29.

    CAS  PubMed  Google Scholar 

  135. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23–31.

    Google Scholar 

  136. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106. Epub 2011/09/29.

    CAS  PubMed  Google Scholar 

  137. Hon KL, Wang SS, Leung TF. What happens to the severity grading by objective SCORAD if we over- or underestimate disease extent or intensity in patients with atopic dermatitis? Int J Dermatol. 2012;51(3):295–9. Epub 2012/02/22.

    PubMed  Google Scholar 

  138. Oranje AP, Stalder JF, Taieb A, Tasset C, de Longueville M. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child. Pediatr Allergy Immunol. 1997;8(1):28–34.

    CAS  PubMed  Google Scholar 

  139. Gelmetti C, Colonna C. The value of SCORAD and beyond. Towards a standardized evaluation of severity? Allergy. 2004;59 Suppl 78:61–5.

    PubMed  Google Scholar 

  140. Tremp M, Knafla I, Burg G, Wuthrich B, Schmid-Grendelmeier P. ‘EASIdig’ – a digital tool to document disease activity in atopic dermatitis. Dermatology. 2011;223(1):68–73. Epub 2011/08/26.

    PubMed  Google Scholar 

  141. Schmitt J, Langan S, Williams HC. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol. 2007;120(6):1389–98.

    Google Scholar 

  142. Holm EA, Wulf HC, Thomassen L, Jemec GB. Assessment of atopic eczema: clinical scoring and noninvasive measurements. Br J Dermatol. 2007;157(4):674–80.

    Google Scholar 

  143. Vourc’h-Jourdain M, Barbarot S, Taieb A, Diepgen T, Ambonati M, Durosier V, et al. Patient-oriented SCORAD: a self-assessment score in atopic dermatitis. A preliminary feasibility study. Dermatology. 2011;66(8):1114–21.

    Google Scholar 

  144. Ricci G, Dondi A, Patrizi A. Useful tools for the management of atopic dermatitis. Am J Clin Dermatol. 2009;10(5):287–300.

    PubMed  Google Scholar 

  145. Armstrong AW, Kim RH, Idriss NZ, Larsen LN, Lio PA. Online video improves clinical outcomes in adults with atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol. 2011;64(3):502–7. Epub 2011/01/18.

    PubMed  Google Scholar 

  146. Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, et al. Patient-oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011;66(8):1114–21. Epub 2011/03/19.

    PubMed  Google Scholar 

  147. Meni C, Bodemer C, Toulon A, Merhand S, Perez-Cullell N, Branchoux S, et al. Atopic dermatitis burden scale: creation of a specific burden questionnaire for families. J Eur Acad Dermatol Venereol. 2013;27(11):1426–32. Epub 2013/05/17.

    Google Scholar 

  148. Nijsten T. Dermatology life quality index: time to move forward. J Invest Dermatol. 2012;132(1):11–3. Epub 2011/12/14.

    CAS  PubMed  Google Scholar 

  149. Maksimovic N, Jankovic S, Marinkovic J, Sekulovic LK, Zivkovic Z, Spiric VT. Health-related quality of life in patients with atopic dermatitis. J Dermatol. 2012;39(1):42–7. Epub 2011/11/03.

    PubMed  Google Scholar 

  150. Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985–2010. PLoS One. 2011;6(4):e17520. Epub 2011/05/03.

    PubMed Central  CAS  PubMed  Google Scholar 

  151. Misery L, Finlay AY, Martin N, Boussetta S, Nguyen C, Myon E, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology. 2007;215(2):123–9.

    CAS  PubMed  Google Scholar 

  152. Ganemo A, Svensson A, Lindberg M, Wahlgren CF. Quality of life in Swedish children with eczema. Acta Derm Venereol. 2007;87(4):345–9.

    PubMed  Google Scholar 

  153. Hon KL, Kam WY, Lam MC, Leung TF, Ng PC. CDLQI, Scorad and Ness: are they correlated? Qual Life Res. 2006;15(10):1551–8.

    Google Scholar 

  154. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. Br J Dermatol. 2006;154(4):719–25.

    CAS  PubMed  Google Scholar 

  155. Brenninkmeijer EE, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, Bos JD. The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol. 2009;26(1):14–22.

    PubMed  Google Scholar 

  156. Augustin M, Wenninger K, Amon U, Schroth MJ, Kuster W, Chren M, et al. German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results. Dermatology. 2004;209(1):14–20.

    PubMed  Google Scholar 

  157. Vieths S, Bieber T. Personalised medicine for the diagnosis and treatment of allergic diseases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(11):1531–7. Epub 2013/10/31. Personalisierte Ansatze zur Diagnostik und Therapie von Allergien.

    CAS  PubMed  Google Scholar 

  158. Broich K, Bieber T. Personalised medicine. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(11):1465–7. Epub 2013/10/31. Personalisierte Medizin.

    CAS  PubMed  Google Scholar 

  159. Bieber T, Broich K. Personalised medicine. Aims and challenges. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(11):1468–72. Epub 2013/10/31. Personalisierte Medizin. Zielsetzungen und Herausforderungen.

    CAS  PubMed  Google Scholar 

  160. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475–82. Epub 2012/10/31.

    CAS  PubMed  Google Scholar 

  161. Suzuki Y, Kodama M, Asano K. Skin barrier-related molecules and pathophysiology of asthma. Allergol Int. 2011;60(1):11–5. Epub 2011/01/22.

    CAS  PubMed  Google Scholar 

  162. Bieber T, Cork M, Reitamo S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy. 2012;67(8):969–75. Epub 2012/06/08.

    CAS  PubMed  Google Scholar 

  163. Wu LC, Zarrin AA. The production and regulation of IgE by the immune system. Nat Rev Immunol. 2014;14(4):247–59. Epub 2014/03/15.

    CAS  PubMed  Google Scholar 

  164. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132(1):110–7. Epub 2013/05/08.

    Google Scholar 

  165. Nahm DH, Kim ME. Treatment of severe atopic dermatitis with a combination of subcutaneous allergen immunotherapy and cyclosporin. Yonsei Med J. 2012;53(1):158–63. Epub 2011/12/22.

    PubMed Central  CAS  PubMed  Google Scholar 

  166. Novak N, Thaci D, Hoffmann M, Folster-Holst R, Biedermann T, Homey B, et al. Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract–a new therapeutic option for patients with atopic dermatitis. Int Arch Allergy Immunol. 2011;155(3):252–6. Epub 2011/02/05.

    PubMed  Google Scholar 

  167. Darsow U, Forer I, Ring J. Allergen-specific immunotherapy in atopic eczema. Curr Allergy Asthma Rep. 2011;11(4):277–83. Epub 2011/04/05.

    CAS  PubMed  Google Scholar 

  168. BuBmann C, Bieber T, Novak N. Systemic therapeutic options for severe atopic dermatitis. J Dtsch Dermatol Ges. 2009;7(3):205–19.

    PubMed  Google Scholar 

  169. Niebuhr M, Kapp A, Werfel T. Specific immunotherapy (SIT) in atopic dermatitis and food allergy. Hautarzt. 2008;59(7):544–50.

    Google Scholar 

  170. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007;7(6):542–56.

    CAS  PubMed  Google Scholar 

  171. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006;61(2):202–5.

    CAS  PubMed  Google Scholar 

  172. Bieber T. Off-label prescription in atopic dermatitis. Allergy. 2015;70(1):6–11.

    Google Scholar 

  173. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429–38. Epub 2013/11/26.

    CAS  PubMed  Google Scholar 

  174. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. Response to a randomized trial of methotrexate vs. azathioprine for severe atopic eczema: a critical appraisal. Br J Dermatol. 2012;166(4):704. Epub 2012/03/29.

    Google Scholar 

  175. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353–9. Epub 2011/04/26.

    CAS  PubMed  Google Scholar 

  176. Schmitt J, Schakel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol. 2007;87(2):100–11.

    CAS  PubMed  Google Scholar 

  177. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment of adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(7):130–9.

    Google Scholar 

  178. Bieber T. Stratified medicine: a new challenge for academia, industry, regulators and patients. London: Future Science; 2013. Available from: http://www.futuremedicine.com/doi/book/10.2217/9781780843186.

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Allergy, Center of Translational Medicine, University of Bonn, Sigmund Freud Str. 25, Bonn, 53105, Germany

    Thomas Bieber MD, PhD, MDRA

Authors
  1. Thomas Bieber MD, PhD, MDRA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Bieber MD, PhD, MDRA .

Editor information

Editors and Affiliations

  1. Department of Dermatology and Allergy, Center of Translational Medicine, University of Bonn, Bonn, Germany

    Thomas Bieber

  2. St. John's Institute of Dermatology, London, United Kingdom

    Frank Nestle

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bieber, T. (2015). Personalized Management of Atopic Dermatitis: Beyond Emollients and Topical Steroids. In: Bieber, T., Nestle, F. (eds) Personalized Treatment Options in Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45840-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45840-2_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45839-6

  • Online ISBN: 978-3-662-45840-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation